Apogee Therapeutics Inc (NASDAQ: APGE) is -18.98% lower on its value in year-to-date trading and has touched a low of $30.84 and a high of $72.29 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The APGE stock was last observed hovering at around $40.46 in the last trading session, with the day’s loss setting it -3.76%.
Currently trading at $36.70, the stock is -18.96% and -23.28% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.03 million and changing -9.29% at the moment leaves the stock -24.82% off its SMA200. APGE registered 12.68% gain for a year compared to 6-month loss of -25.42%. The firm has a 50-day simple moving average (SMA 50) of $48.1919 and a 200-day simple moving average (SMA200) of $48.960773.
The stock witnessed a -17.53% gain in the last 1 month and extending the period to 3 months gives it a -33.13%, and is -25.42% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.94% over the week and 7.06% over the month.
Distance from 52-week low is 19.00% and -49.23% from its 52-week high. The company has generated returns on investments over the last 12 months (-19.72%).
The EPS is expected to grow by 7.87% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
213.0 institutions hold shares in Apogee Therapeutics Inc (APGE), with institutional investors hold 144.09% of the company’s shares. The shares outstanding are 45.02M, and float is at 36.31M with Short Float at 22.27%. Institutions hold 127.29% of the Float.
Apogee Therapeutics Inc (APGE) Insider Activity
The most recent transaction is an insider sale by HENDERSON MICHAEL THOMAS, the company’s Chief Executive Officer. SEC filings show that HENDERSON MICHAEL THOMAS sold 15,000 shares of the company’s common stock on Jan 08 ’25 at a price of $48.85 per share for a total of $0.73 million. Following the sale, the insider now owns 1.31 million shares.
Still, SEC filings show that on Jan 02 ’25, Dambkowski Carl (Chief Medical Officer) disposed off 4,085 shares at an average price of $46.94 for $0.19 million. The insider now directly holds 255,348 shares of Apogee Therapeutics Inc (APGE).
